Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | PLAT-02 and -05 trials for CAR-T in R/R infant ALL

Colleen Annesley • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T
PLAT-02 PLAT-05

Colleen Annesley, MD, Seattle Children’s Research Institute, Seattle, WA, discusses two clinical trials, PLAT-02 (NCT02028455) and PLAT-05 (NCT03330691), exploring the use of CAR T-cell immunotherapy for infants with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Results show successful manufacture and administration of a CAR T-cell products in most infant patients, while toxicity and MRD negative complete remission rates were comparable to that of older children or adolescents with ALL. In addition, Dr Annesley reveals that infant patients with R/R ALL are not at increased risk for lineage switch relapse. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Colleen Annesley

1:46
Novel CD19t T-APCs enhance CD19 CAR T-cell persistance
Colleen Annesley • 7 Dec 2019
0:53
Challenges in treating infant ALL patients with CAR-T
Colleen Annesley • 7 Dec 2019

Related Videos

2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals